Improved survival achieved by HIV-infected patients has complicated their medical care, as increasing numbers of comorbidities have led to polypharmacy and a higher risk of drug–drug interactions. Here, evidence is provided that weight-loss drugs should be used with caution in HIV-infected patients treated with lipophilic antiretroviral drugs because of the risk of virologic failure. This is particularly relevant considering that these agents are available on the market as over-the-counter medications, thus escaping the control of the physician.
|Titolo:||Loss of Control of HIV Viremia With OTC Weight-Loss Drugs: A Call for Caution?|
GIACOMELLI, ANDREA (Secondo)
|Parole Chiave:||Medicine (miscellaneous); Endocrinology, Diabetes and Metabolism; Endocrinology; Nutrition and Dietetics|
|Settore Scientifico Disciplinare:||Settore MED/17 - Malattie Infettive|
|Data di pubblicazione:||ago-2018|
|Digital Object Identifier (DOI):||10.1002/oby.22240|
|Appare nelle tipologie:||01 - Articolo su periodico|